Compare Stocks: HIND, CNTB, MREO, and IMA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTB Connect Biopharma	$0.93 +6.4%	$1.78	$0.85 ▼ $3.82	$58.31M	-0.16	1.44 million shs	1.20 million shs
HIND Vyome	$2.05 -2.2%	$2.11	$1.75 ▼ $6.56	$14.36M	1.53	286,067 shs	3,687 shs
IMA ImageneBio	$4.18 -1.5%	$5.13	$3.90 ▼ $9.10	$47.40M	0.74	126,381 shs	13,116 shs
MREO Mereo BioPharma Group	$0.32 -7.7%	$0.31	$0.20 ▼ $2.37	$51.74M	0.2	5.26 million shs	783,337 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTB Connect Biopharma	0.00%	-6.15%	-57.35%	-61.50%	-53.23%
HIND Vyome	0.00%	+9.42%	+1.46%	-6.70%	-58.78%
IMA ImageneBio	0.00%	-7.83%	-16.54%	-30.61%	-46.73%
MREO Mereo BioPharma Group	0.00%	-7.87%	+24.96%	+9.00%	-82.15%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTB Connect Biopharma	$0.93 +6.4%	$1.78	$0.85 ▼ $3.82	$58.31M	-0.16	1.44 million shs	1.20 million shs
HIND Vyome	$2.05 -2.2%	$2.11	$1.75 ▼ $6.56	$14.36M	1.53	286,067 shs	3,687 shs
IMA ImageneBio	$4.18 -1.5%	$5.13	$3.90 ▼ $9.10	$47.40M	0.74	126,381 shs	13,116 shs
MREO Mereo BioPharma Group	$0.32 -7.7%	$0.31	$0.20 ▼ $2.37	$51.74M	0.2	5.26 million shs	783,337 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTB Connect Biopharma	0.00%	-6.15%	-57.35%	-61.50%	-53.23%
HIND Vyome	0.00%	+9.42%	+1.46%	-6.70%	-58.78%
IMA ImageneBio	0.00%	-7.83%	-16.54%	-30.61%	-46.73%
MREO Mereo BioPharma Group	0.00%	-7.87%	+24.96%	+9.00%	-82.15%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTB Connect Biopharma	2.78	Moderate Buy	$5.88	534.45% Upside
HIND Vyome	2.25	Hold	$3.50	71.15% Upside
IMA ImageneBio	2.25	Hold	$29.00	594.61% Upside
MREO Mereo BioPharma Group	2.13	Hold	$1.67	416.00% Upside

Current Analyst Ratings Breakdown

Latest HIND, CNTB, MREO, and IMA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/12/2026	CNTB Connect Biopharma	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$4.00
10/8/2026	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
10/2/2026	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/30/2026	CNTB Connect Biopharma	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$5.00
9/29/2026	MREO Mereo BioPharma Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/25/2026	IMA ImageneBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/24/2026	CNTB Connect Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/22/2026	CNTB Connect Biopharma	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$5.00
9/16/2026	CNTB Connect Biopharma	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$7.00 ➝ $6.00
9/15/2026	CNTB Connect Biopharma	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/14/2026	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$7.00

(Data available from 10/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTB Connect Biopharma	$2.95M	19.75	N/A	N/A	$0.75 per share	1.23
HIND Vyome	$320K	44.86	N/A	N/A	$0.67 per share	3.05
IMA ImageneBio	$800K	59.23	N/A	N/A	$11.91 per share	0.35
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	$0.26 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTB Connect Biopharma	-$55.48M	-$1.19	N/A	N/A	N/A	N/A	-165.41%	-121.58%	11/11/2026 (Estimated)
HIND Vyome	-$10.26M	-$3.37	N/A	N/A	N/A	-3,024.84%	-197.33%	-138.14%	N/A
IMA ImageneBio	-$45.35M	-$4.58	N/A	N/A	N/A	N/A	-38.99%	-34.84%	N/A
MREO Mereo BioPharma Group	-$41.88M	-$0.04	N/A	N/A	N/A	N/A	-74.82%	-64.28%	11/9/2026 (Estimated)

Latest HIND, CNTB, MREO, and IMA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	MREO Mereo BioPharma Group	-$0.01	N/A	N/A	N/A	$4.61 million	N/A
8/12/2026	Q2 2026	CNTB Connect Biopharma	-$0.3149	-$0.27	+$0.0449	-$0.27	$0.74 million	$2.75 million
8/12/2026	Q2 2026	HIND Vyome	N/A	-$0.10	N/A	-$0.10	N/A	$0.27 million
8/12/2026	Q2 2026	MREO Mereo BioPharma Group	-$0.01	-$0.01	N/A	-$0.05	$3.50 million	N/A
8/5/2026	Q2 2026	IMA ImageneBio	-$0.90	-$0.63	+$0.27	-$0.63	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
HIND Vyome	N/A	N/A	N/A	N/A	N/A
IMA ImageneBio	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTB Connect Biopharma	0.01	2.37	2.37
HIND Vyome	N/A	4.37	4.37
IMA ImageneBio	N/A	21.47	21.47
MREO Mereo BioPharma Group	N/A	5.88	5.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTB Connect Biopharma	58.72%
HIND Vyome	22.06%
IMA ImageneBio	75.00%
MREO Mereo BioPharma Group	62.83%

Insider Ownership

Company	Insider Ownership
CNTB Connect Biopharma	22.60%
HIND Vyome	33.00%
IMA ImageneBio	2.22%
MREO Mereo BioPharma Group	6.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTB Connect Biopharma	64	62.97 million	48.74 million	Optionable
HIND Vyome	18	7.02 million	4.70 million	N/A
IMA ImageneBio	18	11.35 million	11.10 million	Not Optionable
MREO Mereo BioPharma Group	39	159.69 million	149.31 million	Optionable

HIND, CNTB, MREO, and IMA Headlines

Recent News About These Companies

Mereo BioPharma Group plc - Sponsored ADR (MREO) - What Are Researchers Thinking About This Stock?

October 12 at 2:44 AM | americanbankingnews.com

Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO) Stock Has Average Target Price of $1.67

October 12 at 2:43 AM | marketbeat.com

Mereo BioPharma Group plc(NasdaqCM:MREO) dropped from S&P Global BMI Index

September 22, 2026 | marketscreener.comM

Mereo BioPharma Group PLC ADR

September 6, 2026 | barrons.com

Mereo BioPharma Group plc: Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung ...

August 11, 2026 | finanznachrichten.de

Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights

August 11, 2026 | markets.businessinsider.com

Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

August 11, 2026 | markets.businessinsider.com

Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

August 11, 2026 | prnewswire.com

Mereo BioPharma Group Corporate Event Calendar | NASDAQ:MREO

July 15, 2026 | benzinga.com

4basebio Announces Appointment of Chief Financial Officer and Board Changes

May 14, 2026 | globenewswire.com

Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates

May 12, 2026 | globenewswire.com

Mereo BioPharma Group plc Sponsored ADR

April 19, 2026 | edition.cnn.com

We're Hopeful That Mereo BioPharma Group (NASDAQ:MREO) Will Use Its Cash Wisely

April 7, 2026 | finance.yahoo.com

MREO DEADLINE TODAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc ...

April 6, 2026 | gazettextra.comG

Class Action Filed Against Mereo BioPharma Group plc (MREO) - April 6, 2026 Deadline to Join – Contact Levi & Korsinsky

April 6, 2026 | globenewswire.com

MREO DEADLINE TODAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important April 6 Deadline in Securities Class Action – MREO

April 6, 2026 | globenewswire.com

MREO DEADLINE ALERT: ROSEN, A LEADING NATIONAL FIRM, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important April 6 Deadline in Securities Class Action - MREO

April 6, 2026 | newsfilecorp.comN

MEREO LAWSUIT DEADLINE TODAY: Bragar Eagel & Squire, P.C. Urges Mereo BioPharma Stockholders with Large Losses to Contact the Firm Regarding Their Rights

April 6, 2026 | globenewswire.com

MREO FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026

April 6, 2026 | businesswire.com

Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO

April 6, 2026 | prnewswire.com

MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm

April 6, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HIND, CNTB, MREO, and IMA Company Descriptions

Connect Biopharma NASDAQ:CNTB

$0.93 +0.06 (+6.44%)

As of 01:30 PM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Vyome NASDAQ:HIND

$2.04 -0.05 (-2.15%)

As of 01:13 PM Eastern

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

ImageneBio NASDAQ:IMA

$4.18 -0.07 (-1.53%)

As of 01:29 PM Eastern

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Mereo BioPharma Group NASDAQ:MREO

$0.32 -0.03 (-7.69%)

As of 01:28 PM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HIND, CNTB, MREO, and IMA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HIND, CNTB, MREO, and IMA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HIND, CNTB, MREO, and IMA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HIND, CNTB, MREO, and IMA Company Descriptions

Connect Biopharma NASDAQ:CNTB

Vyome NASDAQ:HIND

ImageneBio NASDAQ:IMA

Mereo BioPharma Group NASDAQ:MREO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HIND, CNTB, MREO, and IMA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HIND, CNTB, MREO, and IMA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HIND, CNTB, MREO, and IMA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HIND, CNTB, MREO, and IMA Company Descriptions

Connect Biopharma NASDAQ:CNTB

Vyome NASDAQ:HIND

ImageneBio NASDAQ:IMA

Mereo BioPharma Group NASDAQ:MREO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools